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McCune-Albright syndrome is a sporadic disease charac-
terized by polyostotic fibrous dysplasia, cafe´-aux-lait lesions,
and a variety of endocrine disorders (1, 2). The molecular
basis of this syndrome has recently been elucidated. Mis-
sense point mutations in the GNAS1 gene located on the long
arm of chromosome 20 and encoding for the a subunit of Gs
(the G protein that stimulates cAMP) of transmembrane gly-
coprotein receptors have been identified (3, 4). Mutations at
codon 201 substituting Arg with either Cys or His give rise
to abnormal Gsa proteins that reduce the intrinsic guanosine
triphosphatase activity, thereby constitutively activating the
Gs protein. The mutation is found in variable abundance in
different endocrine and nonendocrine tissues, consistent
with the mosaic distribution of abnormal cells generated by
a somatic cell mutation early in embryogenesis. Severe dis-
ease may be associated with an earlier mutational event
leading to more widespread distribution of mutated cells (5).
The most commonly encountered endocrine dysfunction
in McCune-Albright syndrome is gonadal hyperfunction.
Precocious puberty represents the usual initial manifestation
of McCune-Albright syndrome in girls. Ovarian cysts may be
found on pelvic ultrasound (6–8). Other endocrine abnor-
malities include hyperfunction of the thyroid and adrenal
cortex, as well as excessive GH secretion. The majority of
patients have abnormally elevated sex steroids with low or
undetectable gonadotropin levels (5). Whereas pregnancies
have been described later in life (9, 10), polymenorrhea and
amenorrhea due to continued gonadotropin-independent es-
trogen production have also been reported (11). However,
clinical information regarding ovarian dysfunction in Mc-
Cune-Albright patients during adolescent and adult life is
scant.
Case Report
A 22-yr-old patient previously diagnosed as McCune-
Albright attended our outpatient clinic for fertility counsel-
ing. She exhibited the classical clinical triad of polyostotic
fibrous dyplasia along with large cafe´-aux-lait spots in the
lumbosacral region and a history of precocious puberty and
irregular menstrual bleeding.
Computed tomography scans showed fibrous dysplastic
bone in the left humerus as well as in the sphenoid and
maxillary sinus. The field of vision of the left eye was re-
stricted due to facial bone involvement. Furthermore, she
complained of recurrent maxillary sinusitis on the left side.
At the age of 20 she underwent surgery in which dysplastic
bone was removed from her maxillary and ethmoı¨d sinus on
the left side. At age 21 she fractured her left clavicle following
an accident with a horse. Healing was markedly delayed.
Several typical cafe´-aux-lait spots were located in the lum-
bosacral region, having a triangular shape, predominantly
located at the left side and extending from L4 until S3, as well
as in the neck and at the flexor surface of the lower left leg.
Menarche occurred at age 5 along with left-sided breast
enlargement and development of pubic hair. At that time she
exhibited low serum FSH and LH levels, whereas estradiol
(E2) was in the normal adult range. Bone age and height were
normal at the onset of menstruation. Symptoms did not
progress during 5 yr of treatment with cyproterone acetate
(12). Sexual maturation started after cessation of cyproterone
acetate at 10 yr of age and was completed at 15 yr of age.
Thereafter, several combined steroid contraceptive pills were
prescribed for irregular menstrual bleeding without success.
As far as she could remember, her menstrual cycle had been
irregular (bleeding interval, 1–2 weeks) throughout life. Dur-
ing several periods without hormonal contraception she had
unprotected intercourse with different male partners with-
out conceiving a pregnancy. Before consultation she also
suffered from intermittent pelvic pain predominantly on the
right side. On physical examination, her height was 175 cm
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and body weight 58 kg. Pubic hair and breast development,
as well as the appearance of her external genitals, were ac-
cording to Tanner stage V. On transvaginal pelvic ultrasound
several cysts were observed only in the right ovary, together
with a thickened endometrial lining of the uterus and en-
gorged uterine veins. At the time of referral, increased serum
E2 (805 pmol/L), normal FSH (2.6 IU/L), LH (3.0 IU/L), PRL
(3.6 mg/L), TSH (1.6 mU/L), androstenedione (9.4 nmol/L),
and dehydroepiandosteronsulphate (2.4 mmol/L) levels
were found.
Materials and Methods
Ultrasonography
Transvaginal ultrasound was carried out on initial screening and at
2-day intervals during two months. Ovarian volume, number of follicles
and cysts, features of ovulation, and endometrial thickness (anterior and
posterior layers measured in the longitudinal axis) were recorded. For
sonographic imaging we used a 6.5-MHz vaginal transducer (model
EUB-415; Hitachi Medical Corporation, Tokyo, Japan), as described pre-
viously (13, 14).
Source of tissue and preparation of cells
In the beginning of a bleeding period (day 3) laparoscopy and dila-
tation and curettage were performed to collect ovarian and endometrial
biopsies. Before the laparoscopy, several ovarian cysts were punctured
separately using transvaginal ultrasound guidance. Ovarian biopsies
were taken from both ovaries for genetic analysis using monopolar
scissors. Endometrial biopsies were taken using a Pipell microcurette
(Laboratoire CCD, Paris, France). Samples were taken from the anterior
and posterior endometrial wall. All tissue samples as well as the aspi-
rates from cysts were placed in in vitro fertilization (IVF) medium im-
mediately after collection. Aspirates were centrifuged at 3000 3 g for 10
min, and the pellets of cells were reemerged into IVF medium. The
remaining fluid was analyzed for its hormonal content.
Light microscopy
Sections of both ovaries and endometrium obtained by biopsy were
prepared in neutral buffered formalin and embedded in paraffin. There-
after, 10-mm thin sections were cut and subsequently stained with he-
matoxilin and eosin (15).
Hormone assays
Blood samples were obtained by venepuncture during the initial visit
and at 2-day intervals during two monitored months. They were pro-
cessed within 2 h after withdrawal. Serum and aspirates from the cysts
was stored at 220 C. Serum was assayed for FSH, LH, E2, progesterone
(P), testosterone, androstenedione, sex hormone-binding globulin, in-
hibin A, and inhibin B as described previously (16, 17). Normal serum
values were obtained from previous longitudinal studies in 42 normo-
ovulatory volunteers (17, 18). Follicular fluid was assayed for E2 and P.
Normal follicular fluid values were obtained from normo-ovulatory
volunteers (19).
DNA analysis
DNA was extracted from blood lymphocytes, endometrium, left and
right ovarian tissues, and fluid obtained from ovarian follicles and cysts
using commercial kits (QIAGEN, Courtaboeuf, France). PCR was per-
formed on extracted DNAs. With the exception of minor modifications,
we have used a method described previously (20) for selective enrich-
ment of mosaic Arg 201 mutations.
Informed consent
The local Institutional Review Board was informed of the investiga-
tions being carried out. Because only one fully informed patient was
involved, a research potocol approval was not required.
Results
Light microscopy
Microscopic analysis of ovarian biopsies showed primor-
dial, primary, and secondary follicles along with Graaffian
structures most pronounced in the right ovary. Although all
stages of follicular development were present, larger follicles
were luteinized. Secretory as well as proliferative elements
were present side by side in the endometrium (Fig. 1, A
and B).
Mutation analysis
Direct DNA sequencing showed the presence of a guanine
to adenine transversion leading to an Arg-His substitution at
position 201 in the anterior endometrial lining and right
FIG. 1. A and B, The left photomicrograph (magnification, 3400) shows a large cystic structure in the right ovary. Note the luteinized granulosa
cells lining the cyst (A). The right photomicrograph (magnification, 3400) shows the endometrium with proliferative components (B) as well
as secretory elements (C).
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ovary. The mutation was neither detectable in the left ovary
nor in fluid obtained from ovarian cysts, in the posterior
endometrial lining, or in blood lymphocytes.
Both canonical and mutant sequences were present. The
latter with a weaker intensity, indicating a somatic mutation
and, thus, a mosaicism of normal and abnormal cells as
observed in McCune-Albright syndrome.
Cycle 1
In the beginning of this cycle the maximum FSH level
observed was 4.0 IU/L (median during early follicular phase
of normo-ovulatory controls, 5.2 IU/L; range, 2.5–11.2),
whereas LH levels were increased at 15.5 IU/L (median
during early follicular phase of normo-ovulatory controls,
3.2 IU/L; range, 1.9–10.1) (17, 18). The initial ultrasound
investigation on day 5 showed four dominant follicles in the
enlarged (58 mL) right ovary with a diameter ranging be-
tween 14 and 23 mm. Beyond day 9 these follicles ceased
growing at a diameter beyond 25 mm. In contrast, single
dominant follicle selection and normal development could
be observed in the normal sized (18 mL) left ovary. At a
follicle diameter beyond 20 mm signs of ovulation (a sudden
decrease in follicle diameter and the appearance of free fluid
in the pouch of Douglas) could be observed. This occurred
once between the 10th and 15th day and once on day 23. E2
levels were 971 pmol/L on cycle day 7 (median mid follicular
phase in controls, 220 pmol/L; range, 91–462) and decreased
to 467 pmol/L on day 16. Thereafter, an increase was ob-
served up to 930 pmol/L before menses (median late luteal
phase in controls, 169 pmol/L; range, 144–228). P levels were
as high as 9.2 nmol/L in the beginning of the cycle (median
early follicular phase in controls, 1.0 nmol/L; range, 0.2–9.0)
and rose to a peak value of 30.2 nmol/L on day 12 (median
mid luteal phase in controls, 49.5 nmol/L; range, 16.7–60.8).
Subsequently, P levels decreased to a value of 4.5 nmol/L on
cycle day 23. At day 23, LH and FSH levels were 4.3 IU/L and
3.4 IU/L, respectively. The total endometrial thickness was
10 mm on cycle day 10 and decreased to 4.5 mm on day 20.
These results are depicted in Fig. 2A.
Cycle 2
During the second cycle, three distinctive rises in FSH
were observed on cycle day 12 (6.8 IU/L), cycle day 24 (5.9
IU/L), and cycle day 39 (12.3 IU/L). Similarly, rises in LH
were observed on days 12, 24, and 39, reaching values of 12.1
IU/L, 11.7 IU/L, and 50.0 IU/L, respectively. Inhibin B se-
rum concentrations were only determined during the second
cycle because the sample volume during the first cycle was
insufficient. Inhibin B levels increased from early follicular
phase levels of 76 ng/L (median early follicular phase in
controls, 40 ng/L; range, 32–60) to a maximum of 220 ng/L
on cycle days 15 and 17 (median late follicular phase in
controls, 170 ng/L; range, 98–223). Thereafter, inhibin B fell
to a nadir level of 45 ng/L on cycle day 30 with a subsequent
rise to 96 ng/L on cycle day 37. Inhibin A levels were 28 ng/L
on cycle day 3 (median early follicular phase in controls, 7
ng/L; range, 1.1–10.2) and gradually increased to a maxi-
mum value of 49 ng/L on cycle day 32 (median mid to late
luteal phase in controls, 35 ng/L; range, 16–43). Thereafter,
inhibin A decreased to a level of 4 ng/L on cycle day 39. In
the right ovary, multiple dominant follicle development was
observed and again growth was arrested at a diameter
around 25 mm. In the left ovary, single dominant follicle
growth was noted later during the cycle with a maximum
diameter of 22 mm on day 32. E2 levels were 521 pmol/L on
cycle day 3 and remained fairly constant until cycle day 24.
Thereafter, E2 levels fell gradually to a nadir of 69 pmol/L on
cycle day 37. P levels were 4.2 nmol/L on cycle day 3 and
remained fairly constant during the follicular phase. On cycle
day 24 a rise in P levels could be noted up to a peak value
of 44.1 nmol/L reached on cycle day 32. A sharp decline was
noted between days 32 and 39 in this cycle to a level of 5.8
nmol/L. Endometrial thickness was 3.7 mm at initial screen-
ing and increased gradually to 8.4 mm. On ultrasound ex-
amination a triple line was observed throughout the cycle.
During menses the endometrium remained 8.4 mm thick.
These results are depicted in Fig. 2B.
Follicular fluid
In the right ovary five follicles measuring 22, 13, 12, 10, and
10 mm were punctured whereas in the left ovary three fol-
licles with a diameter of 5, 5, and 4 mm were aspirated
separately. E2 and P levels were compared with values ob-
tained from similar follicles from regularly cycling women
(19). Results are summarized in Fig. 3. Intrafollicular E2 and
P concentrations were increased in small follicles (,10 mm)
but diminished in large follicles.
Discussion
Our findings represent the first longitudinal assessment of
ovarian dysfunction in an adult patient suffering from Mc-
Cune-Albright syndrome. The anticipated phenotype is the
development of multiple dominant follicles as a result of
increased FSH signaling. Indeed, FSH levels are increased in
mothers of dizygotic twins resulting from multiple ovula-
tions (21). Next to the development of multiple preovulatory
follicles, premature luteinization and follicle maturation ar-
rest may also be anticipated in this patient due to increased
LH receptor signal transduction. This latter phenomenon
may be comparable with a premature rise in serum LH
observed during initial protocols for ovarian hyperstimula-
tion for IVF without GnRH agonist cotreatment (22).
High FSH levels occurring during the luteo-follicular tran-
sition give rise to continued growth of a limited number
(cohort) of follicles (23). Subsequent development of this
cohort during the follicular phase is dependent on continued
stimulation by gonadotropins. FSH levels decrease during
the follicular phase due to negative feedback by ovarian
inhibin B and E2 synthesis. Except for the dominant follicle
remaining, follicles enter atresia due to insufficient support
by reduced FSH levels (24). During the late follicular phase,
aromatase enzyme activity of granulosa cells from the dom-
inant follicle is also stimulated by LH (25). Under normal
conditions, a good correlation between dominant follicle di-
ameter and follicle fluid or serum E2 levels is observed
(18, 19).
Increased FSH receptor signaling induced multiple dom-
inant follicle development in the right ovary of the current
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patient. Consequently, E2 levels were increased at the be-
ginning of the cycle. In McCune-Albright patients, cyst-like
structures produce E2 in vitro comparable with normal pre-
ovulatory follicles. In contrast, small follicles synthesize sub-
stantially more E2 compared with these cysts (26). In the
current study, follicular fluid E2 levels were increased in
small follicles and decreased in preovulatory follicles com-
pared with normal control subjects. Because McCune-
Albright patients respond well to treatment with aromatase
inhibitors (12), it might be speculated that aromatase is over-
expressed in granulosa cells of McCune-Albright patients
due to constitutive FSH signaling resulting in supraphysi-
ological intrafollicular E2 concentrations.
Follicular fluid P levels were also increased in small fol-
licles whereas in larger preovulatory follicles P concentra-
tions were normal. Due to continuous LH receptor activa-
tion, P is synthetized prematurely by small follicles.
Increasing P production is accompanied by decremental E2
synthesis due to luteinization of granulosa cells. Conse-
quently, growth is arrested, atresia occurs, and these follicles
become cysts due to premature P exposure.
In the left ovary (without the mutation), normal single
dominant follicle growth and normal intrafollicular steroid
levels were found. The follicle reached a normal preovula-
tory diameter and subsequently showed signs of ovulation.
In contrast to the luteo-follicular rise in FSH during the
normal cycle, a dominant follicle emerged in our patient after
a distinct rise in serum FSH during the midfollicular phase
of the cycle. This rise was accompanied by a transient in-
crease in inhibin B like in the normal cycle. While the dom-
inant follicle is growing, E2 output increases coinciding with
the rise in inhibin A (27). Following ovulation, serum P levels
increased along with an increase in inhibin A, suggesting
normal corpus luteum function. Subsequently, P, inhibin A,
and E2 levels decrease, constituting a pattern comparable
with luteolysis in the normal cycle. The overall hormonal
pattern was virtually the same in both cycles monitored.
It seems that some negative feedback activity of inhibin B
FIG. 2. A and B, Schematic presentation of ultrasound findings in both ovaries (top) and endometrium (second panel) during the first (A) and
second (B) observation month. TED, Total endometrial diameter. FSH and LH concentrations are shown in the third panel of each figure. Inhibin
A and inhibin B concentrations are summarized in the fourth panel of B. Finally, E2 and P levels are depicted in the bottom panels of each figure.
Shaded areas on the x-axis indicate periods of “menstrual” bleeding.
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on endogenous FSH levels remains because FSH serum lev-
els decreased after a rise in inhibin B levels during the mid-
follicular phase. LH levels were very low throughout the
cycle. There is, however, no consistent relationship between
LH concentrations and either E2 levels or P levels indicating
appropriate feedback. Collectively, these data suggest that
the feedback mechanism of the pituitary gonadal axis for
FSH is functioning properly in McCune-Albright patients.
Patients presenting with a Gsa “gain of function” mutation
represent a “human model” to study increased signal trans-
duction of gonadotropin receptors. The only activating FSH
receptor mutation was identified in a hypophysectomized
male who remained fertile despite undetectable gonadotro-
pin levels (28). Activating LH receptor mutations have been
described in male-limited precocious puberty, whereas they
do not seem to have any particular phenotype in females (29).
Hence, in females with McCune-Albright syndrome symp-
toms might be due mainly to increased FSH signal trans-
duction. Although the effects of activating FSH receptor mu-
tations in the context of normal pituitary function in the
female are not known, they might resemble the phenotype of
McCune-Albright patients. Indeed, enlarged ovaries with
multiple cysts have been described in women with FSH-
producing pituitary tumors (30). Finally, FSH receptor poly-
morphism seems to be associated with the amount of exog-
enous FSH required for adequate ovarian stimulation for IVF
(31).
This patient showed a typical unilateral involvement of
tissue. The mutation was only found in the right polycystic
ovary. This might be due to the absence or a smaller number
of mutated cells present in the left ovary not being detected
by DNA analysis. This difference in expression of the mu-
tation is compatible with “normal” monofollicular growth in
the left ovary. This ovary might still be dysfunctional as a
result of the abnormal endocrine environment induced by
the right ovary. Removal of the right ovary might restore
normal function of the remaining left ovary and should be
considered. Similarly, differences were observed in distri-
bution of mutated cells throughout the endometrium. Con-
sequently, the endometrium was out of phase presumably
due to elevated P levels throughout the cycle. This implies
that endometrial receptivity is disturbed and natural fertility
is compromised. This may represent an additional cause of
infertility, even in case normal function of at least one ovary
could be restored. This condition might also render future
IVF procedures unsuccessful. Some women with McCune-
Albright syndrome achieve normal menses and fertility, as
well as pregnancies (9–11, 32–34). They might constitute a
subgroup of patients in which the extent of the Gsa-mutated
cells is limited. On the contrary, other patients have persis-
tence of autonomous gonadal function resulting in irregular
cycles, metrorhagia, and other gynecological problems (8, 11,
34). These abnormalities might be underestimated because
the vast majority of papers address clinical findings in
younger patients.
In conclusion, the present report provides evidence for
persistent autonomous unilateral ovarian dysfunction dur-
ing early adulthood in McCune-Albright syndrome not com-
patible with normal fertility. Increased FSH and LH signaling
gives rise to development of multiple dominant follicles,
premature luteinization, anovulation, and cyst formation.
Single dominant follicle development and normal ovulation
and subsequent corpus luteum function could be observed
on the contralateral unaffected ovary. Endometrial morphol-
ogy is abnormal. The gynecological implications of these
findings may include cycle disturbances and untreatable in-
fertility. Extended suppression of endogenous FSH or uni-
lateral ovariectomy should be considered when pregnancy is
desired.
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